Kalyani Vemuri
Postdoktor vid Institutionen för medicinsk biokemi och mikrobiologi; Biokemi och Cancer; Anna-Karin Olsson
- E-post:
- kalyani.vemuri@imbim.uu.se
- Besöksadress:
- BMC
Husargatan 3
752 37 UPPSALA - Postadress:
- Box 582
751 23 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Biografi
Kalyani Vemuri was born in Andhra Pradesh, India in the year 1991. She completed her bachelors studies from the Vellore Institute of Technology, India in 2014 and in 2016 she received her master degree in Molecular Medicine from Uppsala University, Sweden. In 2017, she began her PhD studies under the supervision of Prof. Anna Dimberg at Uppsala University and in 2022, she successfully defended her thesis titled "CD93 in regulation of vascular function and tumour progression". Kalyani is currently employed as a post-doctoral researcher in the research group of Prof Anna-Karin Olsson where she is currently studying the effects of primary tumour on the peripheral organ vasculature.
Publikationer
Senaste publikationer
- Preclinical Photodynamic Therapy Targeting Blood Vessels with AGuIX® Theranostic Nanoparticles (2024)
- CD93 maintains endothelial barrier function and limits metastatic dissemination (2024)
- CD93 maintains endothelial barrier function by limiting the phosphorylation and turnover of VE-cadherin (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- A method for Boolean analysis of protein interactions at a molecular level (2022)
Alla publikationer
Artiklar
- Preclinical Photodynamic Therapy Targeting Blood Vessels with AGuIX® Theranostic Nanoparticles (2024)
- CD93 maintains endothelial barrier function and limits metastatic dissemination (2024)
- CD93 maintains endothelial barrier function by limiting the phosphorylation and turnover of VE-cadherin (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- A method for Boolean analysis of protein interactions at a molecular level (2022)
- ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma. (2021)
- CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis (2018)
- Global gene expression analysis of distant organ vasculature in mice with cancer
- AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis
- CD93 stabilizes endothelial junctions and preserves blood-brain barrier integrity
- CD93 limits VEGFR2 activation and preserves endothelial barrier function in metastatic cancer
- Multispectral imaging identifies CD93 as a tumor endothelial marker associated with vascular proliferation and poor patient survival in glioblastoma
Böcker
